Skip to main content
. 2022 Jun 2;14(3):587–607. doi: 10.1016/j.jcmgh.2022.05.012

Figure 4.

Figure 4

GSK484-mediated blockade of NET formation attenuates ALF in mice. (A) Work flow of pretreatment with the PAD4 inhibitor GSK484 (20 mg kg-1 body weight) in 10-week-old male C57 BL/6J mice with D-GalN/LPS–induced ALF (D-GalN 0.75 mg g-1 body weight, LPS 2.5 μg g-1 body weight). PBS-treated mice served as controls. n = 5–6. (B) Representative images of H&E-stained liver tissue (original magnification, 400×) and the (C) quantification of necrotic area in H&E staining. Scale bar: 10 μm. Serum activity of (D) ALT and (E) AST. (F) mRNA expression level of TNF-α in the liver tissue determined by quantitative PCR. (G, H). Hepatic infiltration of neutrophils was determined by (G) immunohistochemistry of MPO in liver sections as shown in representative images (original magnification, 400×) and (H) semiquantification of the numbers of MPO+ cells under 400× microscopic fields. Scale bar: 10 μm. (I) Immunoblotting analysis of MPO in liver lysate and density ratio of MPO relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as loading control. (J) Survival in 10-week-old male C57 BL/6J mice after intraperitoneal injection of D-GalN (0.75 mg g-1 body weight) and LPS (0.01 μg g-1 body weight) in the presence or absence of GSK484 pretreatment. n = 10 per group. ∗P < .05, ∗∗P < .01.